Fulvestrant Package Insert

Faslodex® (fulvestrant) - Specialty Pharmacy Home Page
1. Faslodex [package insert]. Cheshire, England; AstraZeneca; March 2016. Accessed March 2016. 2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Fulvestrant. National Comprehensive Cancer Network, 2016. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL ... Fetch Full Source

Last Review Status/Date - Media.fepblue.org
Ibrance is a prescription medicine that is used along with aromatase inhibitor or fulvestrant (Faslodex) for the treatment of males and postmenopausal women with estrogen receptor (ER)- Ibrance [package insert]. New York, NY; Pfizer Labs; February, 2016. ... View Doc

Tamoxifen - Wikipedia
On 18 October 2006, the Subcommittee for Clinical Pharmacology recommended relabeling tamoxifen to include information about this gene in the package insert. Certain CYP2D6 variations in breast cancer patients lead to a worse clinical outcome for tamoxifen treatment. ... Read Article

CLINICAL MEDICAL POLICY - Health Options
Products for medically necessary intravenous infusion of Faslodex (fulvestrant). This policy is designed to address medical necessity guidelines that are appropriate for the majority of individuals with a particular disease, illness or condition. ... Read Document

CPAL Technical Bulletin - Cpallab.com
Abbott states in the package insert that testing for cross-reactivity was performed using synthetic specimens containing essentially no Fulvestrant is an estrogen receptor antagonist that binds to the estrogen receptor (ER) in a ... View Doc

10/JF/TW/ONC.000-242-801. 6.0 PACKAGE LEAFLET TEXT FASLODEX ...
PACKAGE LEAFLET TEXT FASLODEX 250mg/5ml, solution for injection Composition One pre-filled syringe contains 250 mg fulvestrant in 5 ml solution. Pharmaceutical Form Solution for injection. Clear, colourless to yellow, viscous solution. ... View Full Source

HIGHLIGHTS OF PRESCRIBING INFORMATION ...
Refer to the Full Prescribing Information for coadministered aromatase inhibitor or fulvestrant for dose modificationsand other relevant safety information. Dose Modificationfor Use with Strong and Moderate CYP3A Inhibitors Avoid concomitant use of the strong CYP3A inhibitor ketoconazole. ... Access Doc

HIGHLIGHTS OF PRESCRIBING INFORMATION ...
2 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1.1 Ovarian Cancer GEMZAR®in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ... Retrieve Document

Collaborative Management Of Patients With Advanced Estrogen ...
Placebo and fulvestrant in women with HR+/HER2- advanced breast cancer whose disease had progressed on prior endocrine therapy • HR = 0.422 Ibrance [package insert]. New York, NY: Pfizer, 2016. Dosing Starting dose 125 mg/day 1st reduction 100 mg/day 2nd reduction 75 mg/day ... Content Retrieval

FDA Approval Of Palbociclib In Combination With Fulvestrant ...
The palbociclib United States package insert for further details regarding the PALOMA-3 trial design (5). Study endpoints The primary efficacy endpoint of PALOMA-3 was investigator-assessedprogression-freesurvival(PFS),definedasthetimefrom the date of randomization to the date of the first documentation ... Read Document

Faslodex® (fulvestrant) - Modahealth.com
1. Faslodex [package insert]. Wilmington, DE; AstraZeneca Pharmaceuticals LP; November 2017. Accessed January 2018. 2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for fulvestrant. National Comprehensive Cancer Network, 2018. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL ... Fetch This Document

HIGHLIGHTS OF PRESCRIBING INFORMATION - BMS
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use YERVOY safely and effectively. See full prescribing information for YERVOY. ... Read Full Source

Specialty In The Pipeline: Oral Oncolytics
Monarch 2: In combination with fulvestrant vs fulvestrant Tafinlar (dabrafenib) [package insert] Novartis Pharmaceuticals Corporation East Hanover New Jersey; January 2018. Tyrosine Kinase Receptor cell differentiation, migration, angiogenesis, cell survival ... Retrieve Doc

: May Result In Bleeding, Death. Monitor Anticoagulant XELODA ...
XELODA tablets should be swallowed whole with water within 30 minutes after a meal. XELODA is a cytotoxic drug. Follow applicable special handling and disposal procedures. 1 If ... Doc Retrieval

IBRANCE (palbociclib) - Caremark
IBRANCE (palbociclib) RATIONALE FOR INCLUSION IN PA PROGRAM . Background . Ibrance is a prescription medicine that is used along with aromatase inhibitor or fulvestrant Ibrance [package insert]. New York, NY; Pfizer Labs; February, 2016. 2. ... Get Doc

References I-123 - Secure.highmark.com
Fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer. Breast Cancer Research And Treatment. Faslodex® (Fulvestrant) for injection [package insert]. Wilmington, DE, AstraZeneca Pharmaceuticals LP. Revised 11/2017. ... Read Full Source

Megace - BMS
By 1.6 pounds. Mean weight changes at 4, and 12 weeks for patients eva8, luable for efficacy in the two clinical trials are shown graphically. ... Access Doc

CLINICAL MEDICAL POLICY - Gatewayhealthplan.com
Products for medically necessary intravenous infusion of Faslodex (fulvestrant). This policy is designed to address medical necessity guidelines that are appropriate for the majority of individuals with a particular disease, illness or condition. ... Return Document

PHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 3/17/16 ...
Letrozole as initial endocrine based therapy in postmenopausal women, or fulvestrant in women with disease progression following endocrine therapy. Palbociclib is the first oral cyclin-dependent kinase (CDK) inhibitor that works by blocking the action of enzymes Package Insert. Revised by ... Document Retrieval